key: cord-0772391-a2bhqt79
authors: Peart Akindele, Nadine; Pieterse, Lisa; Suwanmanee, San; Griffin, Diane E
title: B cell responses in hospitalized SARS-CoV-2-infected children with and without Multisystem Inflammatory Syndrome
date: 2022-04-18
journal: J Infect Dis
DOI: 10.1093/infdis/jiac119
sha: b9c3154df3d60ab4aa45d32e979b94b37138eef4
doc_id: 772391
cord_uid: a2bhqt79

Multisystem inflammatory syndrome in children (MIS-C) can complicate infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but differences in the immune responses during MIS-C compared to coronavirus disease 2019 (COVID-19) are poorly understood. We longitudinally compared the amounts and avidity of plasma anti-nucleocapsid (N) and spike (S) antibodies, phenotypes of B cells and numbers of virus-specific antibody-secreting cells in circulation of children hospitalized with COVID-19 (N=10) and with MIS-C (N=12). N-specific IgG was higher early after presentation for MIS-C than COVID-19 patients and avidity of N- and S-specific IgG at presentation did not mature further during follow up as it did for COVID-19. Both groups had waning proportions of B cells in circulation and decreasing but sustained production of virus-specific antibody-secreting cells for months. Overall, B cell responses were similar, but those with MIS-C demonstrated a more mature antibody response at presentation, suggesting a postinfectious entity compared to COVID-19.

M a n u s c r i p t

Children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are often only mildly symptomatic, but the recognition of Multisystem Inflammatory Syndrome in Children (MIS-C) has called attention to the more severe pediatric clinical manifestations associated with the virus [1] [2] [3] [4] .

MIS-C is characterized by signs and symptoms reflective of intense immune activation with evidence of increased cytokine production similar to that seen in adults with severe and life-threatening forms of coronavirus-induced disease-2019 (COVID-19) [5] [6] [7] [8] [9] [10] . Seropositivity at the time of symptom onset suggests that MIS-C is a post-SARS-CoV-2 inflammatory disease [9] . This possibility is supported by antiviral antibody patterns at the time of hospitalization that show low levels of antiviral IgM and abundant IgG similar to those of adult COVID-19 patients convalescent from mild disease [11] but lower than after severe COVID-19 [12] . Compared to healthy donors or mildly ill patients,

CoV-2 IgG [13] [14] [15] .

Systemic viral infections often lead to a sustained immune response with maintenance of protective titers of neutralizing antibody that correlate with resistance to re-infection [16, 17] . Studies of common cold coronaviruses reveal transient immune memory and studies of adults infected with other beta coronaviruses causing severe respiratory infection such as SARS and MERS indicate that antibody wanes and memory B cells are only present for a few years after recovery in those with mild disease [18] [19] [20] [21] . However, data from adults suggest that more severely affected COVID-19 patients develop higher and more durable titers of virus-specific antibody [22] [23] [24] . One method of evaluating sustained production of antibody associated with a durable immune response is assessment of antibody-secreting cell (ASC) production. Germinal center-matured ASCs can develop into bone marrow-resident long-lived plasma cells and memory B cells capable of providing durable protective immunity [25] [26] [27] [28] [29] . The continued presence of virus-specific ASCs in the peripheral blood is indicative of prolonged output from germinal centers in lymphoid tissue and associated with a durable antibody response [30, 31] . [15] determining the continued production of ASCs over time and the specificity of the antibody produced by these cells will provide insight into immune responses and protection in pediatric patients with MIS-C as compared to those with acute COVID-19.

Here, we use ELISpot assays and document the plasma levels of virus-specific IgG, IgM and IgA, the avidity of the IgG antibody, and the B cell subset phenotypes in pediatric patients hospitalized with acute COVID-19 and MIS-C collected longitudinally. These studies suggest that infection had been more prolonged at the time of hospitalization for children with MIS-C than severe COVID-19, but that virus-specific antibody and B cell responses were otherwise similar.

Patients admitted with suspected SARS-CoV-2 infection to the Johns Hopkins Hospital, were prospectively enrolled into a cohort study entitled, "Clinical Characterization Protocol for Severe Emerging Infections." After informed consent, 80 pediatric participants were enrolled between April 10, 2020, to January 22, 2021. Mean time from admission to enrollment into the study was 3.1 days.

After hospital discharge patients were followed and sampled at 1, 3, and 6 months from study entry, within a predefined window of time.

A c c e p t e d M a n u s c r i p t 6

Peripheral blood was collected in acid citrate dextrose tubes from 53 of those enrolled and PBMCs were isolated using Ficoll-paque gradients, cryopreserved in FBS containing 10% DMSO, and stored in liquid nitrogen as part of the Johns Hopkins Biospecimen Repository. Plasma was frozen at -20 o C and used for the previously reported analysis of cytokines and chemokines [5] and of antibody in this study. Sufficient PBMCs were available in 53 samples from 22 patients (10 COVID-19; 12 MIS-C) for analysis at 2-3 post-entry time points. Studies were performed according to protocols approved by the Johns Hopkins School of Medicine Institutional Review Board.

Protein antigens for antibody-binding assays were prepared from lysates of cells expressing native SARS-CoV-2 N and S proteins as previously described [24] . Briefly, the HEK293F cell line Ftet2 expressing rtTAv16 [32] was transfected with plasmids expressing a doxycycline-inducible codonoptimized SARS-CoV-2 N ORF (pCG144), S ORF (pCG146) or empty plasmid. The S protein matches the original SARS-CoV-2 isolate [33] except for two proline substitutions that stabilize the trimeric prefusion conformation (986KV987 to 986PP987) and three substitutions that eliminate basic amino acids at the S1/S2 cleavage site (682RRAR685 to 682GSAG685). Cells were induced with doxycycline and lysates for use as antigen prepared with 3 freeze-thaw cycles, clarified, and stored at -80ºC. Protein coating concentrations were optimized for sensitivity and specificity using prepandemic plasma, COVID-19 convalescent plasma and control lysates.

Enzyme immunoassays (EIAs) and avidity determinations were optimized and performed as previously described [24, 31] . Briefly, plasma antibody was quantified with indirect EIAs using clear Nunc Maxisorp 96-well plates (Thermo Fisher Scientific) coated with protein lysates from HEK-293

Ftet2 cells expressing S, N or no viral protein diluted in PBS pH 7.4 (S lysate) or 50 mM bicarbonate buffer pH 9.6 (N lysate). After coating overnight with 2 µg lysate/mL at 4°C, plates were washed with PBS containing 0.05% Tween20 (PBST) and blocked at room temperature (RT) with non-fat milk in A c c e p t e d M a n u s c r i p t 7 PBST (5% and 3 h for N; 3% and one hour for S). For measurement of IgM, plasma samples were pre-incubated with protein G agarose (Pierce, Cat. 20398, Thermo Scientific) to deplete IgG. Plasma was serially diluted 2-fold from 1:50 to 1:102,400 and 50 µL added to each well. Plates were incubated at RT for 2 h then washed with PBST. Horseradish peroxidase (HRP)-conjugated secondary antibodies were goat anti-human: IgG (Cat no. Ab6858, Abcam, Cambridge, UK; 1:5000), IgM (µchain-specific, Cat. no. A6907, Abcam), and IgA (α-chain-specific, Sigma-Aldrich; 1:3000) with incubation for one hour at 37°C. OptEIA TMB substrate (Cat. no. 555214, BD Biosciences) was added and incubated at RT in the dark for 15 min before adding 2M H 2 SO 4 as a stop solution. The plates were read at 450 nm. The titer of antibody was determined as the highest dilution with an optical density (OD) three times greater than control.

For analysis of IgG avidity, EIAs were performed as above and after plasma incubation (1:50 dilution), wells were washed with PBST and increasing concentrations (0.5M-7M) of ammonium thiocyanate (NH 4 SCN) were added for 15 min to disrupt the antigen-antibody interaction [34] . Plates were washed, incubated with HRP-conjugated secondary anti-IgG and processed as above. Avidity index was expressed as the concentration of NH 4 SCN required to remove 50% of the bound antibody.

Samples with OD values <0.3 were excluded.

MultiScreen-IP 96-well plates (Merck Millipore, Darmstadt, Germany) were coated at 4°C overnight with 10 µg/mL N lysate, S lysate, or Ig capture antibody (Cat. 609-101-130, Rockland, Limerick, PA). Plates washed with PBST were blocked with 10% FBS in RPMI for 2 h at 37°C. PBMCs were thawed, washed, and resuspended in RPMI-1640 supplemented with 2 mM l-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% heat-inactivated FBS. Cells were transferred to blocked/coated plates, incubated 5 h at 37°C and then recovered for flow cytometry. Software (BD Biosciences) and analyzed using FlowJo (Treestar, Ashland, OR). Gating strategy was based on fluorescence minus one stain control as previously described [24] . The percentages of phenotypic B cells were calculated and converted to cell numbers per microliter based on the absolute lymphocyte count.

All data were analyzed with 2-way ANOVA and were considered significant when the p-value was less than 0.05. Figures were generated with GraphPad Prism 8.4.3.

The study was approved by the Johns Hopkins Medicine Institutional Review Board. After informed consent, blood samples were collected in coordination with routine medical care and/or remnant blood samples were retrieved from the clinical laboratory. Table 1 and Supplemental tables 1 and 2.

SARS-CoV-2-specific antibody was measured on 28 plasma samples from patients with MIS-C (2 to 268 days from symptom onset; mean 59±78 days; median 33.5 days) and 25 samples from patients with acute COVID-19 (1 to 337 days from symptom onset, mean 76±90 days; median 38 days) by EIA using lysates from cells producing native forms of S or N protein as antigen (Supplemental Figure 1 and Figure 1 ). IgM and IgA data are reported as OD values (Supplemental Figure 1) and

IgG data as titers defined as the reciprocal of highest dilution of plasma with an OD 3-times background ( Figure 1 ). N-specific IgM peaked at similar times between 8-21 days from symptom onset (Supplemental Figure 1A) . S-specific IgM levels were also similar in both groups with a peak for MIS-C at days 22-42 from symptom onset (Supplemental Figure 1B) . In both groups and for both antigens, levels of IgM were very low after 42 days from illness onset. N-specific IgA followed a similar trend to N-specific IgM, peaking at 8-21 days in those with MIS-C (Supplemental Figure 1C ).

S-specific IgA levels were also similar between the 2 groups (Supplemental Figure 1D) . Patients with A c c e p t e d M a n u s c r i p t 10 MIS-C had higher levels of N-specific IgG early (day 0-42) after symptom onset ( Figure 1A) , while S-specific IgG levels were not significantly different from those of patients with acute COVID-19 ( Figure 1B ). While early timepoints (days 0 to 42 post infection), were evaluated separately for all immunoglobulins, only N-specific IgG showed a significant difference.

Avidity of IgG to both N and S proteins was measured by determining the concentration of the chaotropic agent ammonium thiocyanate (NH 4 SCN) required to disrupt antibody binding by 50% (Figure 2A-B) . Avidity did not change over time in those with MIS-C ( Figure 2C ), while those with acute COVID-19 showed increasing avidity from 2 to 5 months after symptom onset ( Figure 2D ). Mean S-specific avidity was lower than mean N-specific avidity at all time points in both groups (MIS-C, p=0.0014; acute COVID, p=0.0155).

SARS-CoV-2-specific ASCs were detected in all hospitalized children at some point after infection ( Figure 3 ). IgM-secreting N-and S-specific ASCs were present primarily before 22 days in both groups ( Figure 3A-B) . IgA-secreting N-and S-specific ASCs were overall similar between the groups with continued production through late timepoints ( Figure 3C-D) . IgG-secreting N-and S-specific ASCs were present at similar levels in those with MIS-C and acute COVID-19 and continued to be detectable more than 4-5 months after symptom onset ( Figure 4A-B) . Total IgG, IgA and IgMsecreting ASCs were essentially unchanged over time and similar in both groups ( Figure 4C ).

Flow cytometry was performed to better characterize the B cell population phenotypes in the SARS-CoV-2-infected children in this cohort (Figures 5 and 6 ). The proportion of live cells that were B cells was similar in both groups, with the highest proportions in the first three weeks after the onset of symptoms followed by a decrease over time ( Figure 5A ). Analysis of B cell subsets did not identify significant changes in the proportions of B cells that were naïve, antibody-secreting or memory or differences between groups ( Figures 5B-D and 6A-D) . proportions of B cells in circulation and decreasing but sustained production of virus N-and Sspecific ASCs during recovery from infection. Titers of N-specific IgG were higher early in hospitalization for MIS-C patients than COVID-19 patients. IgG avidity was greater for IgG to N than to S in both groups and at all times examined. For patients with MIS-C IgG avidity was high at entry and did not mature further during follow up while for patients with acute COVID-19, avidity of antiviral IgG showed continuing improvement during the 2 to >5 month follow-up. Therefore, MIS-C was associated with a more mature antibody response at the time of hospitalization than acute COVID-19, consistent with a delayed inflammatory response to infection, but long-term production of antiviral antibody was similar.

IgG, elevation of cytokines and chemokines produced by activated myeloid cells, multi-organ damage and response to immunomodulatory therapy [5] [6] [7] 11] . Children with uncomplicated SARS-CoV-2 infection develop IgG antibodies at approximately 1 week from symptom onset with a peak within 2 weeks while, as we have observed for N-specific IgG, children with MIS-C have IgG at the time of symptom onset and hospitalization [13, 35] . It has been presumed that this severe phenotype in children might be associated with a more durable immune response as is true for adults with severe COVID-19 compared to mild disease. We evaluated the persistence of antiviral IgG for up to 11 months from symptom onset (range 1-337 days) and found that antibody to both the S and N proteins was maintained in both groups of children with different manifestations of severe SARS-CoV-2-

A c c e p t e d M a n u s c r i p t Plasma antibody levels are maintained by long-lived plasma cells that are produced from germinal centers in secondary lymphoid tissue and reside primarily in bone marrow. Information on production of virus-specific ASCs was obtained using ELISpot assays on PBMCs and both S-and Nspecific IgG-producing ASCs were continuously detected, although in decreasing numbers over time in both groups of children. The persistent appearance of ASCs in the periphery after infection has been associated with greater durability of antibody responses and varies with different viral infections.

For example, after acute infection with measles virus, ASC production is sustained for more than 5 months from the time of infection and life-long protective immunity is established [17, 31, 36] . In contrast, after infection with respiratory syncytial virus, ASCs can be detected for about 2 months and protection from reinfection is brief [37] [38] [39] [40] . Our previous studies of hospitalized adults with SARS-CoV-2 infection showed that those with more severe disease produced more S-specific ASCs than those with mild disease [24] a difference that we did not detect in our small cohort of hospitalized SARS-CoV-2-infected pediatric patients. This is consistent with the hypothesis that MIS-C is a different disease process than severe COVID-19 and may be explained in part by the fact that we did not study non-hospitalized children with mild disease for comparison.

Avidity maturation is a measure of ongoing stimulation of lymphoid tissue which yields B cells selected for improved antigen binding capacity [25] . In SARS-CoV-2-infected adults and children, disease severity is associated with a more pronounced innate immune response [5, 8] that may facilitate a more robust adaptive immune response [41] [42] [43] [44] including higher affinity antibody. As previously observed for adults [24, 45, 46] , N-protein antibody avidity was higher than S-protein sectional studies of acute MIS-C patients compared to healthy children, plasmablasts and naïve B cells are increased, and memory B cells reduced [15] and a comparison of MIS-C and acute COVID-19 pediatric patients showed that plasmablast frequencies were similar and higher than in healthy adults [14] . In our hospitalized pediatric cohort we noted a decrease in circulating B cells over time, but did not identify differences in the B cell subsets for MIS-C compared to acute COVID-19.

Our study has limitations. The sample size is small due to the rarity of MIS-C as well as the complexity of coordinating follow up for pediatric patients during the peak of the pandemic.

Therefore, it is difficult to apply our findings to the broader population of children affected by this disease. Additionally, we did not study the neutralizing capacity of the antibodies and do not have sequence information on the infecting viruses. Furthermore, we were not able to correlate the longitudinal data with clinical symptoms after hospital discharge or determine the protection from reinfection.

In summary, pediatric patients hospitalized with MIS-C had evidence of a more mature antiviral antibody response with more anti-N IgG and maximal avidity maturation at the time of admission than those with acute COVID-19. Predicted durability of the antiviral antibody response was similar with continued production of virus-specific ASCs for months after infection. Further study is required to determine the relationship of type of clinical disease to the durability of protective immunity in children. A c c e p t e d M a n u s c r i p t M a n u s c r i p t

Epidemiology of COVID-19 among children in China

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Multisystem inflammatory syndrome in U.S. children and adolescents

SARS-CoV-2-related inflammatory multisystem syndrome in children: Different or shared etiology and pathophysiology as Kawasaki disease

Distinct cytokine and chemokine dysregulation in hospitalized children with acute coronavirus disease 2019 and multisystem inflammatory syndrome with similar levels of nasopharyngeal severe acute respiratory syndrome coronavirus 2 shedding

Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection

The immunology of multisystem inflammatory syndrome in children with COVID-19

Differential cytokine signatures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza infection highlight key differences in pathobiology

Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

Humoral signatures of protective and pathological SARS-CoV-2 infection in children

Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19

Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children

Heterogeneity and longevity of antibody memory to viruses and vaccines

Duration of humoral immunity to common viral and vaccine antigens

Duration of antibody responses after severe acute respiratory syndrome

Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

Antibody response and disease severity in healthcare worker MERS survivors

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Continued virus-specific antibody-secreting cell production, avidity maturation and B cell evolution in patients hospitalized with COVID-19

Germinal centers

Plasma cell and memory B cell differentiation from the germinal center

Role of germinal centers for the induction of broadly-reactive memory B cells

The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation

Bone marrow is a major site of long-term antibody production after acute viral infection

Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques

Tet-on systems for doxycycline-inducible gene expression

A pneumonia outbreak associated with a new coronavirus of probable bat origin

HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection

Antibody responses to SARS-CoV-2 in patients with COVID

Observations made during the epidemic of measles on the Faroe Islands in the year 1846

Longitudinal active sampling for respiratory viral infections across age groups

Serum antibody decay in adults following natural respiratory syncytial virus infection

Immunity to and frequency of reinfection with respiratory syncytial virus

Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults

Extrafollicular antibody responses

Viral epitope profiling of COVID-19 patients reveals crossreactivity and correlates of severity

Humoral Immune Response to SARS-CoV-2 in Iceland

Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities

Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019

We thank Dr. Deborah Persaud for establishing the pediatric cohorts, Christine Atik for assisting with retrieving participant laboratory data, Debra Hauer for laboratory assistance and Dr. Stephen Gould and Chenxu Guo for supplying lysates of N and S protein-producing cells.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t